February 3, 2011 – Behrman Capital, a private equity investment firm based in New York and San Francisco, has acquired Atherotech, a cardiometabolic testing services provider. Atherotech offers the VAP (Vertical Auto Profile) advanced lipid profile test.
The transaction closed on Dec. 23, 2010. The equity capital for the acquisition came from Behrman Capital IV L.P., with debt financing provided by MidCap Financial.
The VAP Test provides direct, detailed measurements of the lipid subclasses that cause cardiovascular disease. It was developed by Jere Segrest, M.D., director of the atherosclerosis research unit at the University of Alabama.
VAP technology more accurately identifies people at risk of heart disease than the traditional cholesterol tests developed in the 1970s, and does so at no significant additional cost. The profiles obtained by the test also allow physicians to create individualized treatment plans while continuing to track patients' progress in battling heart disease.
Robert Flaherty, an operating partner at Behrman Capital, will serve as chairman of the Board of Directors at Atherotech. Flaherty has more than 35 years of operating experience in the healthcare field, with particular expertise in the clinical laboratory environment. He previously served as president and CEO of Athena Diagnostics. During his 17-year tenure with the company, he grew Athena’s revenues from $3 million to $110 million and profits from zero to $50 million.
For more information: www.behrmancap.com, www.atherotech.com
October 09, 2019 
